A phase III double-blind, placebo-controlled multicenter study of abciximab in patients undergoing high risk coronary angioplasty (EPIC)

Trial Profile

A phase III double-blind, placebo-controlled multicenter study of abciximab in patients undergoing high risk coronary angioplasty (EPIC)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Abciximab (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 19 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top